Bisacodyl: Difference between revisions
Ostermayer (talk | contribs) (Prepared the page for translation) |
Ostermayer (talk | contribs) (Marked this version for translation) |
||
| Line 2: | Line 2: | ||
<translate> | <translate> | ||
==Administration== | ==Administration== <!--T:1--> | ||
<!--T:2--> | |||
*Type: [[Special:MyLanguage/laxative|laxative]] | *Type: [[Special:MyLanguage/laxative|laxative]] | ||
*Dosage Forms: tablet, enema, suppository | *Dosage Forms: tablet, enema, suppository | ||
| Line 11: | Line 12: | ||
==Adult Dosing== | ==Adult Dosing== <!--T:3--> | ||
<!--T:4--> | |||
*5-30mg PO daily | *5-30mg PO daily | ||
*10mg suppository daily | *10mg suppository daily | ||
==Pediatric Dosing== | ==Pediatric Dosing== <!--T:5--> | ||
<!--T:6--> | |||
*6-11 yrs: 5mg or rectally daily | *6-11 yrs: 5mg or rectally daily | ||
==Special Populations== | ==Special Populations== <!--T:7--> | ||
<!--T:8--> | |||
*[[Special:MyLanguage/Drug Ratings in Pregnancy|Pregnancy Rating]]: A | *[[Special:MyLanguage/Drug Ratings in Pregnancy|Pregnancy Rating]]: A | ||
*[[Special:MyLanguage/Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out | *[[Special:MyLanguage/Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out | ||
===Renal Dosing=== | ===Renal Dosing=== <!--T:9--> | ||
<!--T:10--> | |||
*Adult: | *Adult: | ||
*Pediatric: | *Pediatric: | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== <!--T:11--> | ||
<!--T:12--> | |||
*Adult: | *Adult: | ||
*Pediatric: | *Pediatric: | ||
==Contraindications== | ==Contraindications== <!--T:13--> | ||
<!--T:14--> | |||
*Allergy to class/drug | *Allergy to class/drug | ||
*Appendicitis | *Appendicitis | ||
| Line 44: | Line 51: | ||
*Gastroenteritis | *Gastroenteritis | ||
==Adverse Reactions== | ==Adverse Reactions== <!--T:15--> | ||
===Serious=== | ===Serious=== <!--T:16--> | ||
<!--T:17--> | |||
*Colonic atony | *Colonic atony | ||
===Common=== | ===Common=== <!--T:18--> | ||
<!--T:19--> | |||
*Abdominal discomfort/colic, diarrhea, proctitis (with suppository use) | *Abdominal discomfort/colic, diarrhea, proctitis (with suppository use) | ||
==Pharmacology== | ==Pharmacology== <!--T:20--> | ||
<!--T:21--> | |||
*Half-life: 8 hr | *Half-life: 8 hr | ||
*Metabolism: Metabolized to BHPM in the colon | *Metabolism: Metabolized to BHPM in the colon | ||
| Line 62: | Line 72: | ||
==Mechanism of Action== | ==Mechanism of Action== <!--T:22--> | ||
<!--T:23--> | |||
*Stimulates peristalsis via parasympathetic reflexes | *Stimulates peristalsis via parasympathetic reflexes | ||
==Comments== | ==Comments== <!--T:24--> | ||
==See Also== | ==See Also== <!--T:25--> | ||
<!--T:26--> | |||
*[[Special:MyLanguage/Constipation|Constipation]] | *[[Special:MyLanguage/Constipation|Constipation]] | ||
==References== | ==References== <!--T:27--> | ||
<!--T:28--> | |||
*Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763] | *Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763] | ||
*Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084] | *Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084] | ||
| Line 83: | Line 96: | ||
*Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831] | *Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831] | ||
<!--T:29--> | |||
<references/> | <references/> | ||
[[Category:Pharmacology]] [[Category:GI]] | [[Category:Pharmacology]] [[Category:GI]] | ||
</translate> | </translate> | ||
Latest revision as of 21:24, 6 January 2026
Administration
- Type: laxative
- Dosage Forms: tablet, enema, suppository
- Dosage Strengths: tablet: 5mg; enema: 10mg/30mL; suppository: 10mg
- Routes of Administration: PO, PR
- Common Trade Names: Dulcolax, Correctol, BisacEvac, Bisacolax, Codulax, Alophen, Feen A Mint, Fleet Stimulant Laxative, Laxit, Modane
Adult Dosing
- 5-30mg PO daily
- 10mg suppository daily
Pediatric Dosing
- 6-11 yrs: 5mg or rectally daily
Special Populations
- Pregnancy Rating: A
- Lactation risk: infant risk cannot be ruled out
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Appendicitis
- Bowel obstruction
- Gastroenteritis
Adverse Reactions
Serious
- Colonic atony
Common
- Abdominal discomfort/colic, diarrhea, proctitis (with suppository use)
Pharmacology
- Half-life: 8 hr
- Metabolism: Metabolized to BHPM in the colon
- Excretion: Urine and bile
Mechanism of Action
- Stimulates peristalsis via parasympathetic reflexes
Comments
See Also
References
- Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
- Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
- Christie J, Rose S. Constipation, diarrhea, hemorrhoids, and fecal incontinence. In: Pregnancy in gastrointestinal disorders. Bethesda (MD): ACG Monograph American College of Physicians; 2007. p. 4–9. Available at https://www.acg.gi.org
- Ducodyl (bisacodyl) [prescribing information]. Troy, MI: Prime Marketing; received January 2019.
- Friedrich C, Richter E, Trommeshauser D, et al, "Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate Into Human Breast Milk: An Open-Label, Parallel-Group, Multiple-Dose Study in Healthy Lactating Women," Drug Metab Pharmacokinet, 2011, 26(5):458-64. [PubMed 21697613]
- "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics.1997;99(2):268-278. [PubMed 9024461]
- Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-274. [PubMed 24345831]